Advertisement

Supportive Care in Cancer

, Volume 20, Issue 3, pp 625–632 | Cite as

The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA

  • Sherry L. Wolf
  • Debra L. Barton
  • Rui Qin
  • Edward J. Wos
  • Jeff A. Sloan
  • Heshan Liu
  • Neil K. Aaronson
  • Daniel V. Satele
  • Bassam I. Mattar
  • Nathan B. Green
  • Charles L. Loprinzi
Original Article

Abstract

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20).

Methods

Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items.

Results

A majority of the 199 patients accrued to this study reported “quite a bit” to “very much” numbness (57%) or tingling (63%) in the hands compared to “a little” or “not at all” (numbness (43%), tingling (38%)). Fewer patients reported “quite a bit” to “very much” shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities.

Conclusions

In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.

Keywords

Chemotherapy-induced peripheral neuropathy EORTC QLQ CIPN20 Cytotoxic agents Numbness Tingling Shooting/burning pain 

Notes

Acknowledgment

This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-63848, CA-35195, CA-37417, CA-35448, CA-35267, CA-63849, CA-35113, CA-35103, CA-35415, CA-35431, CA-45377, and CA-67575. This work was also supported by the NIH Mentorship Grant CA-124477. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institute of Health.

Conflict of interest disclosure

Neil K. Aaronson, who developed the EORCT QLQ-CIPN20 instrument, works with EORTC. The other authors declare no conflict of interest.

References

  1. 1.
    Cavaletti G et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150PubMedCrossRefGoogle Scholar
  2. 2.
    Cavaletti G et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9(4):443–447PubMedCrossRefGoogle Scholar
  3. 3.
    Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625PubMedGoogle Scholar
  4. 4.
    Pace A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79PubMedCrossRefGoogle Scholar
  5. 5.
    Rowinsky EK et al (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115PubMedGoogle Scholar
  6. 6.
    Verstappen CC et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563PubMedCrossRefGoogle Scholar
  7. 7.
    Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12(5):565–571PubMedCrossRefGoogle Scholar
  8. 8.
    Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46PubMedCrossRefGoogle Scholar
  9. 9.
    LoMonaco M et al (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239(4):199–204PubMedCrossRefGoogle Scholar
  10. 10.
    Nikcevich DA et al (2008) A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol 26(15):4009Google Scholar
  11. 11.
    Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRefGoogle Scholar
  12. 12.
    Binder A et al (2007) Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43(18):2658–2663PubMedCrossRefGoogle Scholar
  13. 13.
    Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142PubMedCrossRefGoogle Scholar
  14. 14.
    Cata JP et al (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72(3):151–169PubMedGoogle Scholar
  15. 15.
    Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2 Suppl 1):S8–S19PubMedCrossRefGoogle Scholar
  16. 16.
    NCI Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events version 3.0. National Cancer Institute, BethesdaGoogle Scholar
  17. 17.
    Serlin RC et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284PubMedCrossRefGoogle Scholar
  18. 18.
    Barton D et al. (2011) A double blind, placebo controlled trial of a topical treatment for chemotherapy induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care Cancer. 2010 May 25. [Epub ahead of print]Google Scholar
  19. 19.
    Nunnally J, Bernstein I (1994) Psychometric theory, 3rd edn. McGraw-Hill, New YorkGoogle Scholar
  20. 20.
    Liu H et al (2008) Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: a pooled analysis of 2,440 patients (pts). J Clin Oncol 26:9534Google Scholar
  21. 21.
    Reeves B et al (2010) Natural history of paclitaxel-associated acute pain syndrome (P-APS): NCCTG trial N08C1. J Clin Oncol 28:15s (suppl; abstr 9135). doi: 10.1200/JCO.2010.33.0308
  22. 22.
    Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162–173PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Sherry L. Wolf
    • 1
  • Debra L. Barton
    • 1
  • Rui Qin
    • 1
  • Edward J. Wos
    • 2
  • Jeff A. Sloan
    • 1
  • Heshan Liu
    • 1
  • Neil K. Aaronson
    • 3
  • Daniel V. Satele
    • 1
  • Bassam I. Mattar
    • 4
  • Nathan B. Green
    • 5
  • Charles L. Loprinzi
    • 1
  1. 1.Mayo Clinic RochesterRochesterUSA
  2. 2.Medcenter One Health SystemBismarckUSA
  3. 3.Netherlands Cancer InstituteAmsterdamThe Netherlands
  4. 4.Wichita Community Clinical Oncology ProgramWichitaUSA
  5. 5.Missouri Valley Cancer ConsortiumOmahaUSA

Personalised recommendations